Zura Bio (NASDAQ:ZURA) Price Target Raised to $11.00 at Chardan Capital

Zura Bio (NASDAQ:ZURA) had its price objective lifted by Chardan Capital from $10.00 to $11.00 in a research report released on Monday,Benzinga reports. The firm currently has a buy rating on the stock.

Other equities analysts have also recently issued reports about the stock. Wedbush began coverage on shares of Zura Bio in a research report on Monday, February 9th. They set an “outperform” rating and a $15.00 price objective for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Zura Bio in a research note on Friday, January 9th. Oppenheimer lowered their price target on shares of Zura Bio from $16.00 to $15.00 and set an “outperform” rating for the company in a report on Friday. Finally, Leerink Partners upgraded Zura Bio to a “strong-buy” rating in a research note on Sunday, November 23rd. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $11.60.

Zura Bio Stock Up 1.3%

Zura Bio stock opened at $5.57 on Monday. The stock has a market cap of $362.18 million, a PE ratio of -5.25 and a beta of 0.18. Zura Bio has a 12-month low of $0.97 and a 12-month high of $7.44. The business’s 50-day moving average price is $6.18 and its two-hundred day moving average price is $4.59.

Zura Bio (NASDAQ:ZURA) last posted its earnings results on Thursday, March 19th. The company reported ($0.49) EPS for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.31). As a group, analysts expect that Zura Bio will post -0.65 earnings per share for the current year.

Insider Transactions at Zura Bio

In other Zura Bio news, major shareholder Ai Biotechnology Llc acquired 2,000,000 shares of the company’s stock in a transaction that occurred on Thursday, February 26th. The stock was acquired at an average price of $6.25 per share, for a total transaction of $12,500,000.00. Following the acquisition, the insider directly owned 6,552,725 shares in the company, valued at $40,954,531.25. This represents a 43.93% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. 14.23% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Zura Bio

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Allworth Financial LP bought a new position in shares of Zura Bio during the fourth quarter valued at $30,000. Scientech Research LLC bought a new stake in shares of Zura Bio in the third quarter worth $45,000. AQR Capital Management LLC bought a new stake in shares of Zura Bio in the first quarter worth $72,000. Forefront Wealth Partners LLC acquired a new stake in Zura Bio in the third quarter valued at $93,000. Finally, Bank of America Corp DE increased its holdings in Zura Bio by 31.9% in the fourth quarter. Bank of America Corp DE now owns 41,222 shares of the company’s stock valued at $103,000 after purchasing an additional 9,966 shares during the period. 61.14% of the stock is currently owned by institutional investors and hedge funds.

Zura Bio Company Profile

Zura Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation protein bioconjugates for therapeutic and diagnostic applications. Leveraging a proprietary platform for site-specific incorporation of non-canonical amino acids, the company aims to create highly targeted conjugates that improve drug delivery, enhance imaging contrast, and reduce off-target toxicity. Zura Bio’s technology is designed to streamline the manufacturing process by enabling precise attachment of payloads—such as cytotoxic drugs or imaging agents—to protein scaffolds without affecting their native structure or function.

The company’s research and development activities center on expanding its platform across multiple therapeutic areas, including oncology, immunology and rare diseases.